CSIMarket
 


Regeneron Pharmaceuticals Inc   (REGN)
Other Ticker:  
 
 

REGN's Net Income Growth by Quarter and Year

Regeneron Pharmaceuticals Inc 's Net Income results by quarter and year




REGN Net Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 1,197.10 2,229.00 1,149.20 792.00
III Quarter September 1,315.70 1,632.20 842.10 669.60
II Quarter June 852.10 3,098.90 897.30 193.10
I Quarter March 973.50 1,115.20 624.60 461.10
FY   4,338.40 8,075.30 3,513.20 2,115.80



REGN Net Income forth quarter 2022 Y/Y Growth Comment
Regeneron Pharmaceuticals Inc reported drop in Net Income in the forth quarter 2022 by -46.29% to $ 1,197.10 millions, from the same quarter in 2021.
The fall in the forth quarter 2022 Regeneron Pharmaceuticals Inc 's Net Income compares unfavorably to the Company's average Net Income growth of 8.64%.

Looking into forth quarter 2022 results within Major Pharmaceutical Preparations industry 23 other companies have achieved higher Net Income growth. While Regeneron Pharmaceuticals Inc ' s Net Income meltdown of -46.29% ranks overall at the positon no. 1100 in the forth quarter 2022.




REGN Net Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December -46.29 % 93.96 % 45.1 % -19.47 %
III Quarter September -19.39 % 93.82 % 25.76 % 12.6 %
II Quarter June -72.5 % 245.36 % 364.68 % -64.98 %
I Quarter March -12.71 % 78.55 % 35.46 % -3.53 %
FY   -46.28 % 129.86 % 66.05 % -18.86 %

Financial Statements
Regeneron Pharmaceuticals Inc 's forth quarter 2022 Net Income $ 1,197.10 millions REGN's Income Statement
Regeneron Pharmaceuticals Inc 's forth quarter 2021 Net Income $ 2,229.00 millions Quarterly REGN's Income Statement
New: More REGN's historic Net Income Growth >>


REGN Net Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December -9.01 % 36.56 % 36.47 % 18.28 %
III Quarter September 54.41 % -47.33 % -6.15 % 246.76 %
II Quarter June -12.47 % 177.88 % 43.66 % -58.12 %
I Quarter March -56.33 % -2.96 % -21.14 % -53.11 %
FY (Year on Year)   -46.28 % 129.86 % 66.05 % -18.86 %




Net Income forth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #24
Healthcare Sector #80
Overall #1100

Net Income Y/Y Growth Statistics
High Average Low
54.99 % 8.64 % -57.58 %
(Jun 30 2021)   (March 31, 2014)
Net Income forth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #24
Healthcare Sector #80
Overall #1100
Net Income Y/Y Growth Statistics
High Average Low
54.99 % 8.64 % -57.58 %
(Jun 30 2021)   (March 31, 2014)

Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Regeneron Pharmaceuticals Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
1453.73 % 78.01 % -97.02 %
(Mar 31 2014)  


REGN's IV. Quarter Q/Q Net Income Comment
In the IV. Quarter 2022 Regeneron Pharmaceuticals Inc reported drop in Net Income sequentially by -9.01% to $ 1,197.10 millions, from $ 1,315.70 millions released a quarter before.

Although periodic influence commonly energize IV. Quarter 2022 performance, that simply was not enough to recover Regeneron Pharmaceuticals Inc 's IV. Quarter outcome, Thomas  Evans, Major Pharmaceutical Preparations industry expert wrote and continued that average sequential Net Income growth is at 78.01% for Regeneron Pharmaceuticals Inc .

Within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Net Income quarter on quarter growth. While Regeneron Pharmaceuticals Inc 's Net Income growth quarter on quarter, overall rank is 241.


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #7
Healthcare Sector #17
Overall #241
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #7
Healthcare Sector #17
Overall #241
Net Income Q/Q Growth Statistics
High Average Low
1453.73 % 78.01 % -97.02 %
(Mar 31 2014)  


REGN's IV. Quarter Q/Q Net Income Comment
In the IV. Quarter 2022 Regeneron Pharmaceuticals Inc disclosed drop in Net Income sequentially by -9.01% to $ 1,197.10 millions, from $ 1,315.70 millions achived in the previous reporting period.

Those periodic influence which usually energize IV. Quarter 2022 results, could not rescue the IV. Quarter for the Regeneron Pharmaceuticals Inc , Thomas  Evans, Major Pharmaceutical Preparations industry expert pointed out.

Within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Net Income quarter on quarter growth. While Regeneron Pharmaceuticals Inc 's Net Income growth quarter on quarter, overall rank is 241.


Regeneron Pharmaceuticals Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
Cumulative Net Income 12 Months Ending $ 4,338.40 $ 5,370.30 $ 5,686.80 $ 7,933.60 $ 8,075.30
Y / Y Net Income Growth (TTM) -46.28 % -23.23 % -8.36 % 98.15 % 129.86 %
Year on Year Net Income Growth Overall Ranking # 1041 # 1345 # 348 # 95 # 468
Seqeuential Net Income Change (TTM) -19.21 % -5.57 % -28.32 % -1.75 % 15.44 %
Seq. Net Income Growth (TTM) Overall Ranking # 1100 # 2286 # 1523 # 194 # 871




Cumulative Net Income growth Comment
Regeneron Pharmaceuticals Inc 's cumulative 12 months Net Income continue to drop, but on the faster rate at -46.28% year on year, at Dec 31 2022 compare to the -23.23% decrease at Sep 30 2022. If the Regeneron Pharmaceuticals Inc 's fiscal year would end at Dec 31 2022, annual Net Income would be $4,338 millions.

In the Healthcare sector 67 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 1041, from total ranking in previous quarter at 1345.

Net Income TTM Q/Q Growth Statistics
High Average Low
54.99 %
8.64 %
-57.58 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 24
Healthcare Sector # 68
Overall # 1041

Net Income TTM Y/Y Growth Statistics
High Average Low
144.2 %
41.09 %
-72.81 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 24
Sector # 80
S&P 500 # 1100
Cumulative Net Income growth Comment
Regeneron Pharmaceuticals Inc 's cumulative 12 months Net Income continue to drop, but on the faster rate at -46.28% year on year, at Dec 31 2022 compare to the -23.23% decrease at Sep 30 2022. If the Regeneron Pharmaceuticals Inc 's fiscal year would end at Dec 31 2022, annual Net Income would be $4,338 millions.

In the Healthcare sector 67 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 1041, from total ranking in previous quarter at 1345.

Net Income TTM Q/Q Growth Statistics
High Average Low
54.99 %
8.64 %
-57.58 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 24
Healthcare Sector # 68
Overall # 1041

Net Income TTM Y/Y Growth Statistics
High Average Low
144.2 %
41.09 %
-72.81 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 24
Sector # 80
S&P 500 # 1100




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
REGN's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for REGN's Competitors
Net Income Growth for Regeneron Pharmaceuticals Inc 's Suppliers
Net Income Growth for REGN's Customers

You may also want to know
REGN's Annual Growth Rates REGN's Profitability Ratios REGN's Asset Turnover Ratio REGN's Dividend Growth
REGN's Roe REGN's Valuation Ratios REGN's Financial Strength Ratios REGN's Dividend Payout Ratio
REGN's Roa REGN's Inventory Turnover Ratio REGN's Growth Rates REGN's Dividend Comparisons



Companies with similar Net Income drop for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Net Income for the quarter ending Dec 31 2022
Pro Dex Inc-4.97%$ -4.973 millions
Becton Dickinson And Company-24.93%$ -24.926 millions
Te Connectivity ltd -29.86%$ -29.859 millions
Regen Biopharma Inc -39.42%$ -39.423 millions
Regeneron Pharmaceuticals Inc -46.29%$ -46.294 millions
Takeda Pharmaceutical Company Limited-50.23%$ -50.234 millions
Hologic Inc-62.46%$ -62.460 millions
Novartis Ag-71.04%$ -71.043 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

KOS's Profile

Stock Price

KOS's Financials

Business Description

Fundamentals

Charts & Quotes

KOS's News

Suppliers

KOS's Competitors

Customers & Markets

Economic Indicators

KOS's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071